Search Results - "PETROS, John A"

Global Transcriptome Analysis of Formalin-Fixed Prostate Cancer Specimens Identifies Biomarkers of Disease Recurrence by QI LONG, JIANPENG XU, STANIMIROVIC, Aleksandra, SETH, Arun K, PETROS, John A, MORENO, Carlos S, OSUNKOYA, Adeboye O, SANNIGRAHI, Soma, JOHNSON, Brent A, WEI ZHOU, GILLESPIE, Theresa, PARK, Jong Y, NAM, Robert K, SUGAR, Linda

“…Prostate cancer remains the second leading cause of cancer death in American men and there is an unmet need for biomarkers to identify patients with aggressive…”
Get full text

Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment by Arnold, Rebecca S, Fedewa, Stacey A, Goodman, Michael, Osunkoya, Adeboye O, Kissick, Haydn T, Morrissey, Colm, True, Lawrence D, Petros, John A

“…Abstract Background Cancer progression and metastasis occur such that cells with acquired mutations enhancing growth and survival (or inhibiting cell death)…”
Get full text

A mitochondrial DNA mutation influences the apoptotic effect of statins on prostate cancer by Sun, Qian, Arnold, Rebecca S., Q Sun, Carrie, A Petros, John

“…Background Statins, 3‐hydroxy‐3 methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors, are currently the most widely used cholesterol‐lowering drugs…”
Get full text

mtDNA Mutations Increase Tumorigenicity in Prostate Cancer by Petros, John A., Baumann, Amanda K., Ruiz-Pesini, Eduardo, Amin, Mahul B., Sun, Carrie Qi, Hall, John, Lim, SoDug, Issa, Muta M., Flanders, W. Dana, Hosseini, Seyed H., Marshall, Fray F., Wallace, Douglas C.

“…Mutations in the mtDNA have been found to fulfill all of the criteria expected for pathogenic mutations causing prostate cancer. Focusing on the cytochrome…”
Get full text

The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression by Li, Zhenghong, Sun, Carrie, Tao, Sijia, Osunkoya, Adeboye O., Arnold, Rebecca S., Petros, John A., Zu, Xiongbing, Moreno, Carlos S.

“…In our previous study, we observed that androgen deprivation therapy (ADT) may induce a compensatory increase in MAPK or JNK signaling. Here, we tested the…”
Get full text

Molecular characteristics and markers of advanced clear cell renal cell carcinoma: Pitfalls due to intratumoral heterogeneity and identification of genetic alterations associated with metastasis by Obeng, Rebecca C, Arnold, Rebecca S, Ogan, Kenneth, Master, Viraj A, Pattaras, John G, Petros, John A, Osunkoya, Adeboye O

“…Objectives To identify clear cell renal cell carcinoma‐related gene mutations potentially associated with aggressive disease, sarcomatoid differentiation or…”
Get full text

Protein-Coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy by Long, Qi, Johnson, Brent A, Osunkoya, Adeboye O, Lai, Yu-Heng, Zhou, Wei, Abramovitz, Mark, Xia, Mingjing, Bouzyk, Mark B, Nam, Robert K, Sugar, Linda, Stanimirovic, Aleksandra, Williams, Daron J, Leyland-Jones, Brian R, Seth, Arun K, Petros, John A, Moreno, Carlos S

“…An important challenge in prostate cancer research is to develop effective predictors of tumor recurrence following surgery to determine whether immediate…”
Get full text

Quantitative Study of Electroporation-Mediated Molecular Uptake and Cell Viability by Canatella, Paul J., Karr, Joan F., Petros, John A., Prausnitz, Mark R.

“…Electroporation’s use for laboratory transfection and clinical chemotherapy is limited by an incomplete understanding of the effects of electroporation…”
Get full text

Oxidative stress induces ADAM9 protein expression in human prostate cancer cells by SUNG, Shian-Ying, KUBO, Hiroyuki, ANDERSON, Cynthia, JOHNSTONE, Peter, PETROS, John A, MARSHALL, Fray F, ZHAU, Haiyen E, CHUNG, Leiand W. K, SHIGEMURA, Katsumi, ARNOLD, Rebecca S, LOGANI, Sanjay, RUOXIANG WANG, KONAKA, Hiroyuki, NAKAGAWA, Masayuki, MOUSSES, Spiro, AMIN, Mahul

“…The ADAM (a disintegrin and metalloprotease) family is a group of transmembrane proteins containing cell adhesive and proteolytic functional domains…”
Get full text

Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment by Arnold, Rebecca S., Sun, Carrie Q., Richards, Jendai C., Grigoriev, Galina, Coleman, Ilsa M., Nelson, Peter S., Hsieh, Chia-Ling, Lee, Jae K., Xu, Zhiheng, Rogatko, Andre, Osunkoya, Adeboye O., Zayzafoon, Majd, Chung, Leland, Petros, John A.

“…BACKGROUND AND OBJECTIVES Mitochondrial DNA (mtDNA) mutations, inherited and somatically acquired, are common in clinical prostate cancer. We have developed…”
Get full text

Dilutional hyponatremia of TURP syndrome: A historical event in the 21st century by Issa, Muta M, Young, Mark R, Bullock, Andrew R, Bouet, Rafael, Petros, John A

“…To evaluate the risk of hyponatremia and transurethral resection of the prostate (TURP) syndrome after bipolar saline TURP in patients with large-volume,…”
Get full text

Aquaporin-1 Protein Levels Elevated in Fresh Urine of Renal Cell Carcinoma Patients : Potential Use for Screening and Classification of Incidental Renal Lesions by Arnold, Rebecca S., Roberts, David L., Pattaras, John G., Lian, Fei, Ogan, Kenneth, Master, Viraj A., Sreedharan, Shilpa, Petros, John A.

“…Introduction and Objectives. There are over 65,000 new cases of renal cell carcinoma (RCC) each year, yet there is no effective clinical screening test for…”
Get full text

Loss of HOXC6 expression induces apoptosis in prostate cancer cells by RAMACHANDRAN, Sumathi, PENGBO LIU, MORENO, Carlos S, YOUNG, Andrew N, YIN-GOEN, Qiqin, SO DUG LIM, LAYCOCK, Noelani, AMIN, Mahul B, CARNEY, Jeffrey K, MARSHALL, Fray F, PETROS, John A

“…We have performed whole genome expression profiling of 28 patient prostate tumor samples and 12 normal prostate samples and identified 55 upregulated and 60…”
Get full text

Molecular Classification of Renal Tumors by Gene Expression Profiling by Schuetz, Audrey N., Yin-Goen, Qiqin, Amin, Mahul B., Moreno, Carlos S., Cohen, Cynthia, Hornsby, Christopher D., Yang, Wen Li, Petros, John A., Issa, Muta M., Pattaras, John G., Ogan, Kenneth, Marshall, Fray F., Young, Andrew N.

“…Renal tumor classification is important because histopathological subtypes are associated with distinct clinical behavior. However, diagnosis is difficult…”
Get full text

PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer by RUOXIANG WANG, JIANCHUN XU, DONG, Jin-Tang, PETROS, John A, NELSON, Peter S, MARSHALL, Fray F, ZHAU, Haiyen E, CHUNG, Leland W. K, SARAMÄKI, Outi, VISAKORPI, Tapio, SUTHERLAND, William M, JIANGUANG ZHOU, BUER SEN, SO DUG LIM, MABJEESH, Nicola, AMIN, Mahul

“…We report a previously unrecognized prostate-specific protein, PrLZ (prostate leucine zipper), a new member of the Tumor Protein D52 (TPD52) family. The gene…”
Get full text

Incidence and clinical characteristics of lower urinary tract symptoms as a presenting symptom for patients with newly diagnosed bladder cancer by Dobbs, Ryan W, Hugar, Lee A, Revenig, Louis M, Al-Qassab, SiUsama, Petros, John A, Ritenour, Chad W, Issa, Muta M, Canter, Daniel J

“…The incidence of lower urinary tract symptoms (LUTS) as the sole presenting symptom for bladder cancer has traditionally been reported to be low. The objective…”
Get full text

Comparative Cost Analysis: Teleurology vs Conventional Face-to-Face Clinics by Zholudev, Vitaly, Safir, Ilan J., Painter, Mark N., Petros, John A., Filson, Christopher P., Issa, Muta M.

“…To compare costs associated with teleurology vs face-to-face clinic visits for initial outpatient hematuria evaluation. The analysis included 3 cost domains:…”
Get full text

Machine Learning-Enabled Renal Cell Carcinoma Status Prediction Using Multiplatform Urine-Based Metabolomics by Bifarin, Olatomiwa O, Gaul, David A, Sah, Samyukta, Arnold, Rebecca S, Ogan, Kenneth, Master, Viraj A, Roberts, David L, Bergquist, Sharon H, Petros, John A, Fernández, Facundo M, Edison, Arthur S

“…Renal cell carcinoma (RCC) is diagnosed through expensive cross-sectional imaging, frequently followed by renal mass biopsy, which is not only invasive but…”
Get full text

Novel Synthesis and Biological Evaluation of Enigmols as Therapeutic Agents for Treating Prostate Cancer by Garnier-Amblard, Ethel C, Mays, Suzanne G, Arrendale, Richard F, Baillie, Mark T, Bushnev, Anatoliy S, Culver, Deborah G, Evers, Taylor J, Holt, Jason J, Howard, Randy B, Liebeskind, Lanny S, Menaldino, David S, Natchus, Michael G, Petros, John A, Ramaraju, Harsha, Reddy, G. Prabhakar, Liotta, Dennis C

“…Enigmol is a synthetic, orally active 1-deoxysphingoid base analogue that has demonstrated promising activity against prostate cancer. In these studies, the…”
Get full text

Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry by Wang, May D, Nie, Shuming, Xing, Yun, Chaudry, Qaiser, Shen, Christopher, Kong, Koon Yin, Zhau, Haiyen E, Chung, Leland W, Petros, John A, O'Regan, Ruth M, Yezhelyev, Maksym V, Simons, Jonathan W

“…Bioconjugated quantum dots (QDs) provide a new class of biological labels for evaluating biomolecular signatures (biomarkers) on intact cells and tissue…”
Get full text